EVElias Van De Vijver

Elias Van De Vijver

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elias Van De Vijver has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SImBA-SiQuAl: Advancing High-Content High-Throughput Phenotypic Profiling of 3D Microtumours

    by Elias Van De Vijver, Klara Dewitte, Axl Van Alboom, Christophe Ampe, Hans Van Vlierberghe, Marleen Van Troys

    Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research.

  • Open Access

    Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responses

    by Elias Van De Vijver, Kylian Decroix, Delphine Burggraeve, Petra Van Wassenhove, Zenzi De Vos, Christophe Ampe, Lindsey Devisscher, Hans Van Vlierberghe, Marleen Van Troys

    Background and aims Therapeutic outcomes for advanced hepatocellular carcinoma remain inadequate, despite recent advances using immunotherapy. Long-term effectiveness of systemic therapies, including second-line multi-tyrosine kinase inhibitor sorafenib, is limited by resistance mechanisms and adverse effects. Upregulated deubiquitinase UCH-L1 is frequently correlated with poor prognosis in cancers. Here, we investigated the therapeutic potential of combining pharmacological UCH-L1-inhibition with sorafenib in HCC. Methods UCH-L1 expression was analysed in TCGA-LIHC data and patient-derived HCC tissues. Sorafenib and LDN57444 effects were evaluated in vitro in cytotoxicity and invasion assays. Gene and protein expression were examined by RT-qPCR, Western blotting and immunohistochemistry. In vivo efficacy of drug synergy was assessed in an orthotopic xenograft mouse HCC model. Results In silico data-analysis revealed significantly higher UCH-L1 levels in patient HCC tumours versus non-tumour, associated with reduced overall survival. Low-dose sorafenib upregulated UCH-L1 in HCC cell line Hep3B. Paradoxically, this also promoted invasiveness and sustained MEK1/2-ERK1/2-pathway activation. Combining low-dose sorafenib with LDN57444 produced strong synergistic cytotoxicity in vitro, reverted MAPK-activation and suppressed invasion. Consistently, at low sorafenib dose co-treatment with LDN57444 completely inhibited tumour growth of Hep3B xenografts and enhanced sorafenib efficacy. Conclusion LDN57444 sensitises HCC cells to low-dose sorafenib by reverting drug-induced pro-oncogenic signalling and thereby strongly synergises with sorafenib to enhance anti-tumour efficacy in a HCC mouse model. This presents UCH-L1 as a player in treatment-induced adaptive response and supports further exploring UCH-L1-targeting in combination with sorafenib as therapeutic avenue for advanced HCC.


  • Open Access

    SImBA-SiQuAl: advancing high-content high-throughput phenotypic profiling of 3D microtumours

    by Elias Van De Vijver, Klara Dewitte, Axl Van Alboom, Christophe Ampe, Hans Van Vlierberghe, Marleen Van Troys

    SUMMARY: Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research. MOTIVATION: 3D-microtumour assays such as spheroids and organoids are increasingly used in preclinical research. These assays generate rich phenotypic imaging data, but automated quantitative analysis remains a major bottleneck. This limits reproducibility, scalability, and broad adoption for large-scale, high-content phenomics studies. Moreover, it impedes comprehensively addressing biologically relevant phenotypic (heterogeneous) responses in e.g. perturbation studies. SImBA-SiQuAl ( S pheroid Im age B atch A nalysis - Si mba Qu antitative output A na l ysis) is developed to address this gap by providing an open-source, integrated workflow offering solutions in both the image processing and downstream analysis. Together, this enables in-depth quantitative analysis of 3D microtumour phenotypes across experimental settings.